In these patients, EGFR and KRAS mutations as well as EML4/ALK rearrangements are recognized as "drivers" and as targets for therapy.     ///    "24.8% of patients were EGFR mutated (31/125), 21.6% were KRAS mutated (27/125) and 13.6% hadan EML4/ALK rearrangement (17/125). "    ///    The presence of EML4/ALK rearrangement was associated with an increased PE risk..     ///    "Data on the oncogene drivers (EGFR, KRAS or EML4/ALK) of the same patients were collected."    ///    "Data on the oncogene drivers (EGFR, KRAS or EML4/ALK) of the same patients were collected. "